JOURNAL PLEIN JOURBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL PLEIN JOUR
Company Title:
Company Description:
Keywords to Search:
Company Address:	896 Rue DE Puyjalon,BAIE-COMEAU,QC,Canada
ZIP Code: Postal Code:	G5C1N1
Telephone Number:	4185895900
Fax Number:	4185898216
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	20 to 49
Sales Amount:	$2.5 to 5 million
Credit History: Credit Report:	Excellent
Contact Person:	Andre Juteau
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JULIEN SERGE
JULIEN & FRERES BAIE COMEAU INC
JULIEN & FRERES BAIE-COMEAU

Next company profile:
JOURNAL OBJECTIF PLEIN JOUR
JOURNAL LA HAUTE COTE NORD INC
JOURNAL LA HAUTE COTE-NORD INC

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after
Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of . . .
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited